oxidase components translocates to the plasma membrane and induces enzymatic activity?'" probably by causing a conformational change in the flavocytochrome (Fig 1 ) . Finally, a number of oxidase activity-regulating proteins have been identified with a more general function in phagocyte behavior. Cytochrome /7.7.7,q. The flavo-hemeprotein cytochrome hSSs consists of an (Y subunit with a relative molecular weight (Mr) of 22.000, called p22-phox (p from protein and pI7o.r from phagocyte oxidase) and a glycosylated fi subunit with an Mr of 76,000 to 92,000, called gp91-pho.r'.' (Table I) . The exact stoichiometry of these subunits in either the resting state or the active state of the NADPH oxidase is not known. Each cytochrome hSSX molecule contains heme moieties" and flavin-adenine-dinucleotide (FAD)," but the number of these prostetic groups per molecule of cytochrome is also unknown. Spectroscopic studies have indicated that the heme is probably liganded to two histidines.I3 but the position of these amino acids has not been established. One heme may be bound to gp9 1 -phox and another shared between the two cytochrome hSSX subunits," possibly involving histidine-239 of gp91 -pho.r and histidine-94 of p22-phm.'*' Recently, evidence has been obtained that the two hemes have different midpoint potentials, one with E,,, = -225 mV and the other with Em, = 265 mV. The heme group with Em, = 265 mV For personal use only. on November 16, 2017. by guest www.bloodjournal.org From may have an interaction between one of its propionate side chains with arginine-54. 15 The location of the putative FAD binding domain has been deduced from sequence homology between the cytochrome b558 p subunit (gp91-phox) and the ferredoxin-NADP+ reductase flavoenzyme family12~'6~'7 (Table 2). In a similar way, the position of the putative NADPH binding domain has been mapped on gp91-pho~''.'~.'~ ( Table  2) .
The cDNAs of both subunits of cytochrome b558 have been cloned and sequenced, and the genes encoding these proteins have been localized and characterized (Table 1) . The a subunit p22-phox contains 195 amino acids, with hydrophobic helices in the N-terminal half of the protein that could serve as membrane-spanning domains." The CYBA gene for p22-phox is located on chromosome 16. 19 Mutations in this gene lead to a rare, autosomal form of CGD, called A22 CGD.I9 The gp91-phox subunit of cytochrome bS5* contains 570 amino acids, with four or five transmembrane helices and five potential N-linked glycosylation sites in the amino-termina1 region.%" The CYBB gene for gp91-phox is located on the X chromosome." Mutations in this gene account for all cases of X-linked CGD (X91 CGD), which is the most common form of the disease (about 70% of all patients).
Both subunits of cytochrome b558 are usually missing in A22 CGD as well as in X91 CGD.23,24 This indicates that these subunits stabilize each other. Indeed, association of a 65-kD high-mannose precursor form of gp91-phox with p22-phox is required for processing of the carbohydrate side chains in the mature cytochrome b558 complex.25 However, it is not known which regions in p22-phox and gp91-phox are involved in this mutual stabilization.
Two cytosolic proteins specifically expressed in phagocytes have been identified as NADPH oxidase components by their absence in cells from some CGD patientsz6-" and by reconstitution of oxidase activity with recombinant protein in a cell-free system derived from such CGD cells. These cytosolic components are a 47-kD and a 67-kD protein called p47-phox and p67-phox. The cDNAs for these proteins have been cloned and their genes have been localized and ~haracterized~'~~' ( Table 1 ). The NCFl gene encoding p47-phox is located on chromosome 732; mutations in this gene cause the common A47 type of CGD. The NCF2 gene encoding p67-phox is located on chromosome 13'; mutations in this gene cause the rare A67 type of CGD. Both p47-phox (390 amino acids) and p67-phox (526 amino acids) contain two so-called SH3 (src homology region 3) motifs, known to interact with proline-rich regions in protein-protein interaction^.^^ Each protein also contains at least one of such proline-rich regions. Because p47-phox and p67-phon are known to translocate to cytochrome b558 during oxidase activation, research to elucidate the involvement of the SH3 and proline-rich regions in this interaction is in full progress."" Recently, a third member of the phox protein family has been discovered, with an Mr of about 40,000.38~3' This protein is found in a complex with p47-phox and p67-phox in the cytosol of resting neutrophils and translocates with the other two proteins to cytochrome b558 during oxidase activation (Fig 1) . The cDNA for p40-phox shows a sequence encoding a protein of 339 amino acids, with homology in Cytosolic NADPH oxidase components.
the N-terminus to p47-phox and one SH3 region resembling that of p67-phox." Although this protein is now known as p40-phox, any function in the NADPH oxidase has not been established: CGD patients with a mutation in p40-phox are not known, a cell-free system of oxidase activity with recombinant proteins does not need p40-pho~,4'*~' and also an intact cell system of K562 cells transfected with oxidase components does not require transfection with p40-phox."' Recent evidence suggests that p40-phox interacts with p47-phox through the SH3 domain of p40-phox and with p67-phox through the C-terminus of p40-ph0x.~~ Possibly, p40-phox functions by stabilization of p47-phox and p67-phox in the resting state of the cells.
Enzyme activation. In a cell-free NADPH oxidase activation system consisting of neutrophil membranes (containing cytochrome b 5 5 8 ) , neutrophil cytosol fractions, GTP, NADPH, and an amphiphilic agent (sodium dodecyl sulfate [SDS] or arachidonic acid), it has been found that the cytosol contains at least three proteins needed for superoxide generation by this ~y s t e m . '~,~~,~ Two of these proteins have been identified as p47-phox and p 6 7 -p h o~.~' -~~~~
The third one proved to be a low-molecular-weight guanosine triphosphate (GTP)-binding protein called rac.45-48 This protein family has a wide tissue distribution; in neutrophils both p2lracl and p21rac2 are present."' rac probably functions by changing from an inactive, guanosine diphosphate (GDP)-bound state to an active, GTP-bound state in which it can mediate the activation of the NADPH oxidase. Fine-tuning of this process may be mediated by the regulation of GTP/GDP exchange of rac by GDP-dissociation inhibitor (GDI) protein and GDP-dissociation stimulator (GDS) p r~t e i n .~~,~~,~~ Exactly how rac induces oxidase activation is not known, but indications have been found that rac-1 interacts with p67-pho2' and translocates to the membrane after phagocyte a c t i~a t i o n .~' .~~ This process requires cytochrome bSss in the membrane, because it does not occur in the cell-free system with cytochrome b558-deficient membranes or in intact neutrophils that lack cytochrome b558., ' Recently it was shown that rac-1 translocation depends on the presence of p67-p h o~:~ whereas rac-2 translocation takes place only in the presence of p47-phd3 (but see also ref 52). Studies with p47-phox and p67-phox mutant proteins, in the cell-free system and in intact, transfected cells, as well as with neutrophils from CGD patients with mutations in cytochrome b,,,, have proven that p47-phox and p67-phox associate with cytochrome b558 i t~e l f .~~.~' Phosphorylation of p47-phox andor p67-phox, known to occur in activated p h a g o~y t e s , ' '~~~~' *~ may also be necessary for this translocation, eg, by exposing SH3 and proline-rich domains in these proteins that are inaccessible in the p47-p67-p40-phox complex in the cytosol of resting ~e l l s .~~,~~ An attractive model of oxidase activity regulation has been proposed by Taylor et al.'' These investigators used the crystal structure of ferredoxin reductase from spinach leaves to construct a three-dimensional model of the homologous Cterminal half of gp91-phon. A stretch of 20 nonhomologous amino acids (residues 484 through 503) in gp91-phox lies over the nucleotide binding cleft and may have to be displaced to allow NADPH binding. According to this model, interaction of p47-phox andor p67-phox with cytochrome bss8 may result in movement of this 20-amino acid loop, and thus in access of NADPH to its binding site in gp91-phox. Analysis of CGD mutant proteins has provided arguments for this model (see below). Recent evidence suggests that binding of p67-phox to cytochrome bss8 permits electron flow from NADPH to FAD, whereas p47-phox binding is necessary for electron flow from FAD via the heme groups to oxygen.62.63
Finally, another small GTP-binding protein, called rap 1 A, has been identified that is located in phagocyte membranes and co-purifies with cytochrome Affinity of ruplA for cytochrome bSs8 is decreased by protein kinase A-mediated phosphorylation of rap1 A, suggesting that ruplA may modulate NADPH oxidase activity in response to agonists that elevate cyclic adenosine monophosphate (CAMP).'? RuplA mutants locked in a GTP-bound state or in a GDP-bound state both inhibit oxidase activity when transfected into human B lymphocyte^.^^.^^ These cells are the only nonphagocytic cells known to exhibit some NADPH oxidase activity. The transfection studies show that ruplA may regulate oxidase activity in a dynamic cycle, as opposed to ruc, which is active in a locked GTP-bound state.
CGD patients with decreased NADPH oxidase activity due to mutations in TUC, rap or GTPEDP regulating proteins are not known, probably because of the fact that these proteins are involved in several essential cellular functions, such as vesicular transport and cytoskeleton dynamics. Mutations in such proteins may be incompatible with life.
MUTATIONS IN X-LINKED CGD
Mutations in the CYBB gene usually lead to lack of gp91-phox protein expression, due to instability of mRNA and/or instability of protein. NADPH oxidase activity in activated neutrophils from these patients is totally absent (Table 3) . This phenotype of X-linked CGD is called X91". Occasionally, mutations are found that lead to partial loss of protein expression and heme content. The oxidase activity in the activated neutrophils from these so-called X9 1 ~ CGD patients is usually diminished roughly in proportion to the decrease in heme content.@' Finally, a few mutations have been found to yield normal gp91-phox expression with a virtually total lack of oxidase activity. This subtype of CGD is called X91+ CGD.
In the next sections, a summary will be given of all mutations identified in the CYBB gene and known to us at the time of writing this review (June 199.5). Previously unreported mutations were identified as described before (see bold-printed references in the tables). In all cases of proven CGD subtype, the mutation underlying the disease was found, thus excluding a selection bias because of technical reasons. The results show that X-linked CGD is a very heterogeneous disease, caused by a large variety of mutations. Arbitrarily, these have been arranged into deletions and insertions, splice site mutations, missense mutations, and nonsense mutations.
Deletions in the CYBB gene are a frequently encountered cause of X-linked CGD. Table  4 shows that the size of these deletions ranges from 5,000 kb to one single base pair. When the deletions are very large, not only is the CYBB gene affected, but neighboring genes as well. Such patients suffer from other clinical syndromes in addition to CGD, eg, Duchenne muscular dystrophy, retinitis pigmentosa, and McLeod's syndrome (a mild hemolytic anemia with depressed levels of Kell erythrocyte antigens due to defects in the K" system). This has been observed in patients 1 through 4 in Table 4 .20.h9-72 In all but two cases the deletions are family specific and lead to lack of cytochrome b558 expression.
Two very unusual families were identified in which the children each carried different deletions in their CYBB gene. In family IV-1.5, one brother has a 3-kb deletion that removes exon 5 and parts of the neighboring introns; the other brother has a 3.5-kb deletion that removes exons 6 and 7 and parts of the neighboring introns. Sequencing of genomic DNA showed a very small (35 bp) overlap of the two deletions in intron V." In the mother of these patients a somatic mosaicism was found, because her leukocyte DNA contained both deletions as well as the normal CYBB sequence. In the DNA of her own mother, only the normal sequence was found. Most likely, therefore, the mutations originated from a single mitotic event in the early embryogenesis of the patient's mother, possibly involving sister chromatide exchange. A similar process may have taken place in the mother of patients IV-Sa and IV-8b. Here again, the two sons carry two different deletions in the CYBB gene. However, because of the large size of these deletions (one of them comprising the entire coding region of CYBB), exact characterization has not yet been performed. The mother of these two last patients was found to carry a somatic mosaicism for the normal sequence and the smallest deletion, but the presence of the Deletions and insertions.
For personal use only. on November 16, 2017. by guest www.bloodjournal.org From largest deletion cannot be determined with simple restriction fragment length polymorphism (RFLP) analysis as long as the normal sequence is also present. These two examples show that the possibility of complicated mosaicisms must be kept in mind when performing genetic studies for applications such as prenatal diagnosis.
In patient IV-30 a deletion of a single guanosine at position 151, 152, or 153 was detected (in the normal sequence, a G is found at all three positions). This may cause a frameshift and an early termination of protein synthesis due to a premature stop codon at amino-acid position 60. However, G153 is the last nucleotide of exon 2. In the genomic DNA, this is followed by another G as the first nucleotide in intron 11. Thus, the G deletion may also affect the donor splice site of this intron and cause skipping of exon 2 during mRNA processing. However, it may be expected that the most 3' G in a stretch of 3 G's (instead of 4 G's) will still be recognized by the mRNA splicing machinery as part of the donor splice site. Additional investigation of the mRNA from this patient is needed to rule out exon 2 skipping. Table 5 shows that insertions in CYBB are less frequently found than deletions, in accord with findings in other genes. 74 Usually, this concerns insertions of one single base pair. In patient V-5 we found a 40-bp insertion at the intron VI-exon 7 bo~ndary.'~ This proved to be a 40-bp repeat, probably caused by unequal crossing-over during meiosis. This mutation predicts incorporation of 13 additional amino acids into gp91-phox, followed by 23 changed amino acids and a premature termination of protein synthesis caused by a frameshift. Recently, a 4-nucleotide repeat in exon 2 was found (patient V-I).
A complicated combination of a 5-bp deletion with an 8-For personal use only. on November 16, 2017. by guest www.bloodjournal.org From For explanation see legend to Table 4 . Abbreviation: insert, insertion.
bp insertion was recently described in Japan.76 As Table 5 shows, this predicts substitution of glutamine-lysine-threonine 507-509 by histidine-isoleucine-tryptophan-alanine. The gp91-phox mutated protein is stable, because the net result is an in-frame insertion of one amino acid, resulting in an X91' CGD phenotype of the patient. Translocation of p47-phox and p67-phux to cytochrome b,,, in intact, activated patients' neutrophils was normal. The lack of oxidase activity of this protein77 may be due to disturbed binding of NADPH to gp91phox, because the mutation is in the putative binding region of NADPH (Table 2) , but this has not yet been checked. Large deletions and insertions (>20 bp) are generally considered to be caused by meiotic or mitotic recombination between chromosomes misaligned at partially homologous sequences. Such sequences may act as "hotspots" for such events. Overall, we found no apparent hotspots for the breakpoints of CYBB gene deletions. This may be due to the incomplete characterization of the large deletions and to the relatively small number of well-characterized partial CYBB gene deletions.
Deletions and insertions of single base pairs often occur in runs of identical nucleotides because of slipped mispairing at the DNA replication fork." This was especially evident in single base-pair deletions in CYBB, which we found to occur in stretches of identical bases in 7/9 cases (78%), but was also noted in 215 single base-pair insertions in this gene (40%). Slipped mispairing during DNA replication may also account for the other short (<20bp) deletions and insertions, but the repeat elements or consensus sequences causing this phenomenon are not always easily rec~gnized.~~.~' Krawczak and Cooper79 have identified a human consensus sequence of TG(A/G)(A/G)(G/T)(A/C) frequently involved in deletion events and also serving as an arrest site of polymerase a. This sequence is often associated with palindromic sequences and also with G+C-rich regions. Thus, arrest of DNA synthesis at the replication fork might, by providing a stable singlestranded substrate, serve to increase the probability either of a slipped mispairing event between direct repeats or the formation of secondary structure intermediates that induce dissociation of the polymerase from the template strand and cause deletions or insertions after reassociation. Indeed, we found that this consensus sequence can be identified within two nucleotides of almost all breakpoints of small (<20bp) deletions and insertions in the CYBB gene.
In general, deletions and insertions in CYBB lead to strongly decreased mRNA stability and often to frameshifts, thus causing the clinically severe subtype of X91" CGD.
Only in a few cases of small in-frame deletions (patients IV-17 and IV-19-22), an X91-phenotype was found. Apparently, these mutations weakened the secondary structure of gp91-phox or the association with p22-phon but did not yield a completely instable protein. As mentioned above, the net insertion of one amino acid (patient V-8) resulted in the X91+ CGD subtype.
Defects in mRNA splicing have been estimated to make up 15% of all single base-pair substitutions causing human genetic disease.80 X-linked CGD is no exception in this respect: we and others found 21 patients with partial or complete absence of an exon in gp91-phox mRNA due to splice site mutations, on a total of 135 X-CGD patients (16%). Table 6 shows the complete list. However, in patient VI-16, the aberration in mRNA splicing was caused by a 4-bp deletion rather than to a single base-pair substitution, and in patient VI-21, the splice site mutation has not been formally proven. This last patient lacks about 1 kb of his "A, comprising exon 13 (the last exon of the CYBB gene).*' Possibly, this is caused by a mutation in the 3' (acceptor) splice site at the boundary of intron XII and exon 13.
Also in accord with the literature," mutations in the 5' (donor) splice site predominate: 16 of the 21 patients (76%) had a mutation in the 5' splice site, 4 (19%) in the 3' splice site, and only 1 (5%) novel splice site was observed. In this last case (VI-14), a mutation in exon 6 created a splice site that was apparently preferred over the normal 5' splice site of intron VI. As a result, exon 6 was skipped from the site of the mutation to the 3' end of the exon, which caused a frameshift and a premature stop codon in addition.8 ' We also analyzed how many of the splice site mutations concerned the invariant GT dinucleotide sequence at the 5' end of an intron or the invariant AG sequence at the 3' end of an intron. Of the 16 5' splice site mutations, 7 (44%) were in the GT sequence. This is a rather low percentage compared with the literature figure of 60%.80 However, patients IV-5, IV-6, IV-7, and IV-8 all have the same mutation at position -1 in exon 3. Most likely, these patients are not related to each other, because they live in different countries in Europe, and mutations in X-CGD families can usually be traced only in a few generations. To avoid such identicalSplice site mutations.
For personal use only. on November 16, 2017. by guest www.bloodjournal.org From by-descent mutations, Krawczak et also listed each specific splice site mutation only once. If we do the same, and also neglect patient IV-16 because this is not a point mutation, we also note 60% mutations in the invariant GT sequence. At the 3' splice site, the three characterized mutations all concerned the invariant AG sequence, similar to the literature figure of 87%." It must be realized that mutations in the invariant sequences may give rise to more serious defects in mRNA splicing than those at other positions of the splice sites, and hence be detected easier through their clinical consequences.
MUTATIONS IN CHRONIC GRANULOMATOUS DISEASE
In general, the splice site mutations gave rise to skipping of an entire exon. Only in the case of the novel splice site created in exon 6 (patient IV-14) and in patient IV-20, parts of an exon were removed from the "A.
In this last patient, a cryptic splice site in exon 12 was activated, which resulted in skipping of 30 nucleotides from this exon. This predicts an in-frame deletion of 10 amino acids from the gp91-phox According to the normal amount of this protein on a Western blot and the normal characteristics of cytochrome b558, this patient should be classified as an X91+ CGD patient. However, the neutrophils of this patients showed some residual NADPH oxidase activity (about 6% of normal). Possibly, the 10-amino acid deletion interferes with proper activation of the oxidase, because this deletion is located within the 20-amino acid domain that lies over the NADPH binding cleft. 61 Apart from the four patients with identical splice site mutations, we found no apparent hotspots for this type of mutations in the X-CGD patients. Four (identical) mutations occurred in CpG sequences, and four other splice site mutations (+A) might be due to depurination (see below). However, it is striking that mutations in the splice sites of the first 7 exons are encountered much more frequently than those in the last 6 exons. In general, splice site mutations give rise to decreased levels of mRNA. Complete absence of mRNA was noted in patient IV-21, probably because the removal of exon 13 also leads to loss of the 3' untranslated region of gp9 1-phox mRNA, including the polyadenylation site. Despite the presence of some mRNA in most CYBB splice site patients, all except patient IV-20 displayed the X91" phenotype, probably because of instability of the truncated proteins. Thus, splice site mutations in general lead to a severe form of X-CGD. Table 7 shows that missense mutations, leading to single amino acid replacements, are also frequently found in X-linked CGD. These mutations have no effect on mRNA stability, but affect the level and the function of cytochrome b558 in a variety of ways, leading to either X91", X91-, or X91' CGD. In contrast, nonsense mutations (Table 8) , which induce a stopcodon, always induce the X91" phenotype of CGD, although mRNA levels are affected to various degrees. Together, 71
Missense and nonsense mutations.
patients with single base-pair substitutions outside splice sites have been found, as well as one polymorphism (indicated in Table 7 ). This Gly-364 + Arg polymorphism was found in one male donor and (in heterozygous form) in one female donor among 100 healthy Dutch individuals. In contrast, it was not found in 100 healthy Japanese donors. The granulocytes of the Dutch male donor displayed normal 02-generation, normal amounts of NADPH oxidase components, and normal translocation of cytosolic components to the plasma membrane after activation. The same was found in the cell-free system.82a
A number of mechanisms of single nucleotide substitutions have been identified.'' The best known is methylationinduced deamination of cytosine, which leads to formation of thymidine. Thus, in the sense strand of DNA, this process gives rise to a C -+ T substitution, and in the antisense strand the result is a G -+ A substitution. Deamination of nonmethylated cytidine to uracil also takes place, but is quickly repaired by uracil DNA glycosylase. In contrast, 5-methylcytidine deamination to thymidine does not result in an abnormal constituent of DNA, and is therefore less readily removed by eukaryotic repair mechanisms. Because methylation of cytosine takes place in cytidine-phosphate-guanosine dinucleotides (5' to 3'), also called CpG, the mutations caused by this mechanism are manifested as CG -+ TG and CG -+ CA transitions. Nevertheless, these mutations are difficult to distinguish from those caused by depurination, a process of purine removal from the deoxyribose-phosphodiester backbone by chemical or enzymatic (glycosylase) means. The most frequently removed nucleotide is guanosine, and the most frequently misincorporated base in its place is adenosine. Thus, depurination also leads to G -+ A or C + T, but is not restricted to CpG sequences. Single nucleotide substitutions can also be caused by polymerase-mediated misincorporation of bases during DNA replication, perhaps by a mechanism involving transient base misalignment. In vitro, polymerase a and p have been found to lead to about 60% transitions (purine to purine or pyrimidine to pyrimidine substitutions) and to about 40% transversions (substitution of purine to pyrimidine and vice versa). In evolutionary sequence comparisons, 63% transitions and 37% transversions have been found, indicating that these stable mutations have originated from polymerase defects, and not from repair defects or biased detection.
Analyzing the missense and nonsense mutations in Xlinked CGD (excluding the polymorphism), we found 24/71 = 34% mutations in CpG sequences. This is comparable to the 32% observed with 123 patients with different genetic disea~es.'~ Remarkably, we found no other than G + A and C + T mutations in CpG, contrasting with the l i t e r a t~r e .~~ CpG -+ CA was found only once, in patient VII-18 with a missense mutation, whereas CpG + TG was found in 23 patients with six different nonsense mutations (Table 8) . Arbitrarily, we considered again these mutations to be independent events, not to be identical-by-descent. Always, these CpG + TG nonsense mutations concerned the CGA codon for arginine mutated to the stopcodon TGA. Although one might expect a selection against the CGA codon in favor of the other five codons for arginine, this is not found in the human genome.83 In gp91-phox cDNA, the CGA codon is even twice as much abundant as it is in the genome as a whole. All six CGA codons were found to be mutated in the group of patients listed in Table 8 . As mentioned above, we cannot exclude the possibility that depurination is also involved. Indeed, G + A and C -+ T transitions are found frequently, also outside CpG sequences (in 9 patients each).
At the single nucleotide level, we found 49/71 = 69% transitions and 22/7 1 = 3 1 % transversions. Excluding CpG, these numbers are 26/47 = 55% and 21/47 = 45%, respectively. These data are similar to the ones found in other genetic disease^,'^ but contrast with the expected frequencies of 33% and 67% if the mutations were the result of a random process. Thus, mutations outside CpG in X-linked CGD are also nonrandom, and probably related to misincorporations in the polymerase reaction. The order of mutation frequencies outside CpG was G(17)>C(16)>A(S)>T(6), also in accord with polymerase reactions in vitro (twice as many mutations in C + G as in A + T).
At the dinucleotide level, we analyzed the data by taking into account the mutated nucleotide with either the preceding or the succeeding nucleotide. The observed number of mutations in these dinucleotides was compared with the expected number, based on the frequency of the dinucleotides in the human genome.83 Not surprisingly, CG was found to be 17 times more frequently involved in X-CGD mutations than expected. Other over-involved dinucleotides were CC, GG, GC, CA, and TC (in that order). By and large, this frequency order concurs with that found in other genetic diseases and with the order of stability of dinucleotides. This last fact may be relevant for the stabilization of a transient misalignment to permit misincorporation before realignment occurs.
It is generally assumed that nonsense mutations and frameshift mutations that induce a premature stopcodon lead to dramatic reductions in mRNA levels of that particular protein, with higher levels of mRNA transcripts with termination codons near the 3' end of a gene.84 Although we observed indeed decreased mRNA levels (0% to 50% of normal) associated with nonsense and frameshift mutations in CYBB, we did not find any correlation with the site of the mutation.
For understanding the structure-function relation of gp91-phox, the X91' mutations are extremely important. Here, nature provides us with examples of a stable but nonfunctional protein that can be used to study the content of prostetic groups, substrate binding, interaction with other NADPH oxidase components, interaction with activating, small GTP-binding proteins, etc. Table 7 shows that six different missense mutations are now known to lead to the X91f phenotype. The alanine-57 -+ glutamic acid substitution in patient VII-SS5 is in the N-terminal part of gp91-phox that is probably involved in the interaction with p22-phox and with the plasma membrane. This mutant protein has not been studied for its functional properties.
The other five X91' mutated proteins have been studied in more detail. Segal et allz showed that neutrophil membranes from one of the three known patients with a proline-415 -+ histidine mutation (VII-31 and VII-32) showed decreased binding of the photoaffinity label 2-azido-NADPH at the position of gp91-phox. Because proline-415 is in the putative NADPH-binding region of gp91-phox ( Table 2 , Fig  2) , this result provides a strong argument for the proposed model of gp91-phox as the enzymatic subunit of the NADPH oxidase. Leusen et alS6 later used intact neutrophils and neutrophil membranes of this patient to study the translocation of p47-phox and p67-phox during oxidase activation. A normal translocation was found.
In contrast, strongly decreased translocation of p47-phox and p67-phon was found with the neutrophils and neutrophil membranes of patient VII-33, with an asparagine-500 -+ glycine substitution.x6 This mutation is in the 20-amino acid loop over the NADPH binding pocket in the structural model of Taylor et al' l (Fig 2) . To confirm the importance of this domain for the docking of the cytosolic oxidase components, the investigators also tested the effect of synthetic peptides corresponding to amino acids 491-504 of gp91-phox on the p47-phox and p67-phox translocation in a cell-free activation system with normal neutrophil membranes and cytosolic proteins. The wild-type peptide strongly inhibited translocation and superoxide formation, whereas the Asp-500 -+ Gly substituted peptide was much less effective." These results are in accordance with the model of Taylor et al, which predicts that this loop must be drawn aside by the cytosolic components to give NADPH access to its binding site.
Patients VII-26 and VII-30 have mutations in a loop between the putative regions involved in FAD and NADPH binding and on the edge of the NADPH-binding region, respectively (Fig 2) . Neutrophils from these patients also showed strongly decreased p47-phox and p67-phox translocation. This indicates that several regions in gp91-phox are involved in this process, probably by charge interaction with the cytosolic proteins (Leusen JHW, Keep NH, Hilarius PM, Weening RS, Ahlin A, Sanders L, Verhoeven AJ, Roos 
D, unpublished results, September 1995).
A very interesting X91' patient has recently been described by Cross et al.'"x7 In this patient (V11-5), the Arg-54 -+ Ser substitution affects the heme function of cytochrome b 5 5 8 , as evidenced by a slight shift in optical absorbance properties, a decreased midpoint potential of one heme group from Em, = -265 mV to E,, = -300 mV, and lack of electron transport from FAD to heme in solubilized For personal use only. on November 16, 2017. by guest www.bloodjournal.org From mutant cytochrome bss8 activated by neutrophil cytosol, NADPH and SDS. Translocation of p47-phox and p67-phox to the cytochrome in activated intact cells was normal in this patient. Because no superoxide was produced and neither of the two heme groups seemed to function, this implies that the electron flow from FAD to oxygen requires sequential involvement of the two heme groups.
Eleven patients with nine different mutations are known with point mutations that lead to the X91-subtype of CGD. In most of these, low cytochrome b558 protein and heme expression and low NADPH oxidase activity are uniformly distributed over all neutrophils. In the families VII-1 and VII-2, however, CGD patients have been identified with small subsets (5% to 15%) of neutrophils that display normal oxidase activity and large subsets without detectable oxidase activity.88 In these patients, mutations were found in the 5' A different kind of heterogeneity in the blood cells of an X-CGD patient was recently described by Kuribayashi et al.9' The neutrophils, monocytes, and B lymphocytes of this patient were found to be completely devoid of gp9l-phox protein and mRNA expression as well as NADPH oxidase activity, whereas his eosinophils were completely normal in protein expression and oxidase activity. Sequencing the coding region and the putative poly-A tail signal of the CYBB gene showed no abnormalities. Possibly, this patient has a mutation in a regulatory element of the CYBB gene important for gene transcription in neutrophils, monocytes, and B lymphocytes but not in eosinophils. In addition, normal NADPH oxidase activity in the eosinophils of this patient was apparently insufficient to prevent the clinical symptoms of CGD.
A powerful approach to distinguish between mutations that render the gp9 1-phox protein intrinsically instable and those that lead to a protein unable to associate with p22-phox has been devised by Porter et al. 25 These investigators found that in p22-phox deficient neutrophils and B-lymphocyte cell lines, a 65-kD high-mannose precursor of gp91-phox is present in low amounts. In normal neutrophils, this precursor is processed to the mature glycosylated form of gp9 1-phox. Apparently, association with p22-phox is needed for this terminal processing. Analysis of X91-and X91" patients in this way revealed a number of mutations that disrupt association with p22-phox (65-kD precursor of gp91-phox present) or result in intrinsic instability of gp91-phox (no precursor pre~ent).'~" With this method, exon 3 of gp91-phox, cysteine-244 (close to the putative heme-binding histidine-239) and histidine-338 (within the putative FAD-binding domain) have been recognized as important regions of subunit interaction within cytochrome bSs8.
The list of different mutations leading to X-linked CGD clearly illustrates the very heterogeneous nature of these defects. In fact, 106 different mutations have been found in 135 families with this disease. Figure 3 shows that the single base-pair mutations are scattered over the entire coding region and intron-exon boundaries of the CYBB gene. Only a few hotspots for these mutations can now be recognized, mainly in CpG sequences. Because only one polymorphism within the coding region of the CYBB gene is known, it appears that the gp9 1 -phox polypeptide is extremely sensitive to mutations.
Conclusions.

MUTATIONS IN AUTOSOMAL CGD
Mutations in p22-phox. Table 9 shows that at present, nine families have been investigated with autosomal CGD due to mutations in CYBA, the gene that encodes the small subunit p22-phox of cytochrome b558. This gene has six exons." The table shows that a variety of mutations gives rise to this type of CGD, including deletions, insertions, splice site mutations, and missense mutations. Usually, the level of mRNA for p22-phox is unaffected, except in patient IX-1 in which a large deletion removed all but the extreme 5' coding sequence of CYBA.'' In this patient, p22-phox mRNA was undetectable.
In all but one patient, expression of p22-phox protein was undetectable, because of intrinsic instability of the mutated protein or to decreased interaction with gp91-phox. Of special interest is the histidine-94 -+ arginine substitution in patient IX-5, which removes the histidine that is probably involved in heme binding. I4,l9 Although p22-phox contains two histidines, His-72 is polymorphic and may be replaced by tyrosine without an effect on NADPH oxidase activity." Because p22-phm protein expression was not observed, the His-94 substitution apparently affects the stability of p22-phox and/or the association with gp9l-phox as well, perhaps as a consequence of decreased heme binding between the two cytochrome bSs8 subunits.I4'
In one patient, however, a homozygous proline-156 -+ glutamine substitution was found that left heme binding and association with gp91-phox intact. Thus, patient IX-9 suffers from A22+ CGD.92 Recently, the reason for the oxidase inactivation in this patient has become clear. The Pro-156 is in a proline-rich region that serves as a binding site for an SH3 domain in p47-phon. Independently, three groups have shown, in the cell-free activation system5' as well as in transfected cells" and in the patients' neutrophil^,^' that the Pro-156 --* Glu mutation abolishes the association of p47-phox with p22-phox. Thus, the translocation of p47-phox and p67-phox to cytochrome b,,,, needed for activation of oxidase activity, depends on interaction with both the p22-phox and the gp91-phon subunit of the cytochrome. In the former case, this depends on SH3 binding to a proline-rich region, in the latter case probably on charge interaction.5x38h
The Pro-156 -+ Glu substitution is the first recognized mutation that disturbs an SH3-proline interaction and leads to a genetic disease. Altogether, 10 different mutations have been found in nine A22 CGD families (18 alleles). In seven families, homozygous deficiencies were found, in two families compound heterozygous patients were characterized. Only in two patients from different families, the same mutation was found. Thus, this type of CGD is again very heterogenous in nature. Moreover, only four polymorphisms have been recognized in the reading frame of p22-phox thus far.'9.9' Apparently, small changes in the structure of p22-phox already lead to intrinsic instability or loss of coupling to gp91-phox.
The NCFl gene that encodes p47-phox has 9 exons.94 In contrast to the large heterogeneity found in X91 and A22 CGD, only four different mutations are known so far to cause A47 CGD. In 15 unrelated CGD patients with p47-phox deficiency, a dinucleotide deletion was found at a GTGT tandem repeat, corresponding to the first four bases of exon 2.94-97 Eleven of these patients have a homozygous GT deletion, which predicts a frameshift and premature translation termination after the synthesis of a 50-amino acid peptide. The other 4 patients are compound heterozygotes for this GT deletion in combination with point mutations, ie, A179 -+ G predicting threonine-53 -+ alanine, Mutations in p47-phox.
A425 --* G leading to lysine-135 -+ glutamate replacement, or (3-502 deletion predicting a frameshift and premature stop codon. In Amsterdam we have analyzed the cDNA of 22 A47" CGD patients. In all cases, the GT deletion was found, apparently in the homozygous form.
However, the problem with the characterization of the mutations in this form of CGD is that polymerase chain reaction (PCR)-amplified cDNA or genomic DNA from all healthy control individuals not only contains a product with the expected GTGT sequence, but also a product with the GT deletion. This may indicate that a pseudogene with the GT deletion exists in addition to a complete, functional NCFl gene in normal genomic DNA.9s However, PCR amplification of a GTGT-containing clone induced the GT deletion in a large proportion of the subclones, indicating that the PCR itself induces the same deletion as that found in the patients (Casimir C, Bu-Ghanim H, Segal AW, unpublished results, May 1991). A screening method for the GT deletion with the restriction enzyme DraIII, which cuts only the GTGT-containing ~equence,'~ works well to distinguish homozygous GT deletion patients from healthy control donors (no reaction with patients, 50% reaction with controls) but is too insensitive to detect heterozygous GT deletions.
If the GT deletion is caused by a process within the normal gene, slipped mispairing during DNA replication may be in~olved'~ because inverted repeat sequences are present around the GTGT repeat in the genomic DNA of the NCFl gene.97 Judging from Northern blots with mRNA isolated from mononuclear leukocytes or Epstein-Barr virus (EBV)-transfected B lymphocytes, the mRNA for p47-phox is always present in apparently normal amounts and with a normal size. 30.71.94.95 In all patients analyzed thus far, protein blots probed with antibodies against p47-phox show no reaction. This indicates that all four mutations lead to the synthesis of an unstable protein.
A large number of polymorphisms have been detected in the NCFl coding sequence, most of them silent but some predicting amino acid substitutions (S. Chanock, personal communication, July 1993). Hence, the p47-phox protein is
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Only a few mutations in NCF2, a gene with 16 exons that encodes p67-phox," have been characterized in detail. Most A67 CGD patients have normal amounts of mRNA for p67-phox but lack expression of protein.3i.i" The first mutation to be recognized concerned a homozygous G233 + A substitution in exon 3, predicting a glycine-78 + glutamate replacement.Im Both parents and a sister of the patient proved to be heterozygotes for this mutation. Recently, mutations in two other A67" patients have been reported. The first one concerned a homozygous T --t C mutation at position 2 of the 5' splice site on intron 111, explaining the lack of exon 3 sequences in the mRNA."' Relatives of the patient were not investigated. This case differs from the first one in that the cellular concentration of p67-phox mRNA was drastically reduced, probably because of accelerated breakdown by lack of ribosome protection. The second one concerned a Japanese patient with an AG dinucleotide insertion at position 399-401 in exon 5 of the NCF2 gene, predicting a frameshift and premature termination of p67-phox synthesis.Io2 Both parents were found to be heterozygous for this mutation. In a fourth A67 patient, we have found a GAA deletion, predicting a deletion of lysine-58, in one allele and an 11-to 13-kb deletion in the other allele. Most notably, the neutrophils of this patient contained about half-normal amounts of p67-phox protein. In conclusion, the heterogeneity in the molecular causes of A67 CGD seems to be larger than that of A47 CGD.
Mutations in p67-phox.
NEW DEVELOPMENTS
Genetic basis of clinical heterogeneity. The clinical severity of a genetic disease is determined by the biochemical consequences of a mutation as well as by environmental factors. Therefore, it is not always possible to predict the clinical course of a patient's disease once his or her mutation is known. In CGD, this is particularly difficult because not only the NADPH oxidase enzyme but also other antimicrobial host defense systems are involved in reducing the incidence and extent of infections. A number of studies have shown that X-CGD patients, in general, follow a more severe clinical course than autosomal CGD patient^,"^-"^ perhaps because of some residual superoxide formation by the neutrophils from A47" and A67" patients." It might be expected that patients with the X91-phenotype, with 10% to 30% of residual oxidase activity in their phagocytes,68 might have less severe clinical problems than those with the X91" phenotype. However, this is not a general rule; perhaps auxiliary antimicrobial systems play a decisive role in this respect.
Female carriers of X-CGD mutations may present with clinical manifestations of the disease indistinguishable from those of hemizygous patients. This is due to unequal inactivation of X chromosomes carrying the mutation and those with a normal CYBB gene. Carriers with less than 15% of normal phagocytes may be prone to infections, but again, this is not a general rule.'" Tables 4 through 8 show that female X-CGD patients are found within the groups with missense and nonsense mutations, but not in those with with deletions, insertions, or splice site mutations. The reason for this discrepancy is not known.
In a patient clinically suspected of CGD, the definite diagnosis is made by demonstrating absent or strongly reduced oxidase activity in activated neutrophils. Many different methods are available for this purpose.73 A very convenient assay is the nitroblue tetrazolium (NBT) test, which scores the oxidase activity per cell as positive, weak, or absent.lo8 This test has the additional advantage of being able to detect the female carriership of X-linked CGD, because it will show a mosaic of positive and negative neutrophils in these individuals. Similar assays are available with flow-cytometric technique^.'^*'^ However, because of the random process of X-chromosome inactivation, X-CGD carriers may show a near-normal pattern (90% to 100% oxidase-positive cells) or a near pathologic pattern (0% oxidase-positive cells). Moreover, about one third of all X-linked defects arise from new mutations in germ-line cells, and will therefore not be present in the somatic cells of the mother. Therefore, failure to detect these carriers does not disprove the X-linked origin of the disease.
Further differentiation of CGD into subtypes needs to be performed in a specialized laboratory. This includes immunoblot analysis of neutrophil fractions with antibodies against oxidase components and analysis of membrane and cytosol fractions in the cell-free oxidase assay. A47 CGD and A67 CGD are usually detected by absence of immunoblot staining with the appropriate antibodies, but the presence of + and -variants must be kept in mind. Distinction between A22 CGD and X91 CGD in this way is more problematic, because both subunits of cytochrome 6558 are absent in A22" as well as in X91" CGD,23s24 and + and -variants are known to exist (see preceding sections). When both subunits are undetectable, distinction can usually be made by searching for a mosaic pattern in the NBT test in female relatives of the patients, which proves the X-linked nature of the defect. If this is also negative, mutation analysis of both the CYBA and the CYBB gene is indicated. When both subunits of cytochrome b558 as well as p47-phox and p67-phox are detectable, the cell-free oxidase assay will distinguish between a membrane-bound defect (p22-phox or gp91-phox) and a cytosolic defect (p47-phox or p67-phox).
Carrier detection of the autosomal subtypes of CGD is difficult. At the cellular level we have found that the oxidase activity of phorbol myristate acetate-stimulated neutrophils from obligate heterozygotes of A47" and A67" CGD is significantly lower than that of neutrophils from healthy control donors.'"."" However, this is a rather insensitive assay that has not been tested with carriers of A22 CGD. Once the family-specific mutation in one of the oxidase genes is known, camer detection is much better performed at the DNA level. Unfortunately, as discussed in the preceding section, even this test is not yet operative in a foolproof way for detection of A47 CGD carriers.
Classification of CGD and carrier detection is useful priDiagnosis, postnatal and prenatal.
For personal use only. on November 16, 2017. by guest www.bloodjournal.org From marily for the purpose of genetic counseling and prenatal diagnosis. In the past, in utero fetal blood sampling and NBT testing of fetal neutrophils has been used for prenatal diagnosis of CGD."' However, this technique cannot be used before 16 to 18 weeks of gestation, which means secondtrimester abortions for women with affected fetuses. DNA analysis of amniotic fluid cells or chorionic villus biopsies now provides an earlier and more reliable diagnosis for families at risk.
In case of complete or partial gene deletion, Southern blot analysis of DNA treated with restriction enzymes and probed with labeled cDNA of the appropriate oxidase component will suffice to identify patients. More subtle abnormalities require RFLP analysis. Within the CYBB gene, two Nsi I RFLPs have been recognized,112-"4 as well as several highly polymorphic (GT/AC),
In combination with PCR amplification, these markers offer a very sensitive and more than 50% reliable method for prenatal diagnosis of X-CGD. Within the NCF2 gene, an RFLP has been discovered after digestion with HindIII. 99 The most reliable approach to prenatal diagnosis involves the identification of the family-specific mutation(s) followed by analysis of fetal DNA for the mutant allele(s). This method has been applied by us in five pregnancies at risk for X-linked CGD of the fetus. In all cases, the fetal origin of the DNA was checked with markers for X and Y chromosomes, and linkage studies with RFLPs in and around the CYBB locus confirmed the diagnosis with greater than 98% reliability."7 In 3 cases, all within one family, we showed the CGD status of a male fetus. In each of these cases, the family chose for abortion. In one of these, as well as in a normal pregnancy carried to term, the prenatal diagnosis was confirmed by NBT testing of blood neutrophils.
Treatment of CGD patients is aimed at prevention and aggressive treatment of infections. The use of prophylactic antibiotics, especially sulphamethoxazole-tmethophrim, is very effecBecause Aspergillus infections are still a major tive. 104.1 18-120 cause of death in CGD patients, prophylactic use of itraconazole has also been advocated. Treatment includes prompt surgical drainage or resection of abscesses and early and prolonged use of parenteral antibiotics. In life-threatening situations, daily white blood cell transfusions can be given,' l9 even intralesional.122 Allogeneic bone marrow transplantation has been attempted, but with little success because of severe transplantation complication^.^^'^'^^ A few years ago, a large multicenter study with 128 CGD patients showed that prophylactic treatment with recombinant human y-interferon (rhIFN-y) caused a significant reduction in the number of serious infections.'" Surprisingly, there was no difference in neutrophil superoxide production and killing of Staphylococcus aureus between the rhIFN-r and the placebo group.'05 Hence, IFN-7 appears to boost host defense by enhancing nonoxidative microbicidal mechanisms and/or other aspects of phagocyte function. A followup study has shown that also over a period of up to 4 years, rhIFN-y is well tolerated."' Cautious use of IFN-y in the treatment of CGD patients is outlined in a joint European publication. IZh Because CGD results from single gene defects in a group Treatment, including prospects of gene therapy.
of proteins expressed in myeloid cells, transfer of the correct gene for the defective NADPH oxidase component into pluripotent hematopoietic stem cells would, in principle, constitute definitive therapy. Carriers for X91" CGD with less than 10% of normal neutrophils may be completely healthy,"" suggesting that correction of only a small percentage of the phagocytes in CGD patients may result in clinical improvement or cure. Several investigators have initiated programs to evaluate this possibility. As a first step, EBV-transformed B-cell lines derived from CGD patients have been used for transfection studies with plasmid expression vectors or retroviral constructs containing cDNA for the missing oxidase component. Partial correction of protein expression and NADPH oxidase activity was obtained after prolonged growth in a medium that induced selection of cells cotransfected with a resistance Also in a human myelomonoblastic leukemia cell line with the CYBB gene disrupted by homologous recombination (a "knock-out'' cell line), this technique was able to rescue gp91 -phox protein expression and NADPH oxidase activity.'?' However, these cells are not relevant targets for gene therapy of CGD.
Therefore, the recent publications from Li et all" and Sekhsaria et were important achievements because they showed transduction of CD34' peripheral blood hematopoietic progenitor cells from CGD patients with retroviral vectors containing either p47-phox, p22-phox, or gp9 1 -phox cDNA. These investigators reasoned that long-term growth and expansion of primary hematopoietic progenitor cells is not possible at present without loss of reconstitutive earliest progenitors. Therefore, selection of transduced cells in vitro by use of cotransduced resistance markers offers no advantages. Nevertheless, differentiation in vitro of the transfected cells into mature neutrophils and monocytes resulted in some correction of NADPH oxidase activity.
Although these first experiments are encouraging, there still are a large number of problems to be solved. First, given the small number of progenitor cells that can be processed in vitro in comparison to the remaining, nontreated cells in the bone marrow of the patients, the reconstituted cells will have to compete with an overwhelming majority of genetically deficient cells (about 1 : 100). Hence, selection of transfected cells in vivo may be necessary, for instance by a cotransduced mutant dihydrofolate reductase gene that protects against mild methotrexate treatment. However, chemotherapy in immunocompromised patients may be a dangerous procedure. Second, transcription of introduced DNA sequences that depends on the most commonly used retroviral promoters bears the risk of inactivation in the long run, or, alternatively, of adverse effects induced by expression in other cell types than those normally expressing the gene. Perhaps the use of a myeloid-specific promoter would be preferable over a viral promoter. Regulated expression of the introduced gp9 1-phox cDNA might ideally be achieved by using the promoter of the endogenous CYBB gene, but not all of the cis elements and trans factors required for this process have been fully elu~idated."~'~"''' Finally, integration of retroviral vectors at random carriers the risk of activation or inactivation of other essential genes.
One important development has been the construction of marker. For personal use only. on November 16, 2017. by guest www.bloodjournal.org From a mouse model of X-linked CGD through gene targeting of murine embryonic stem cells.138 A p47-phox knock-out mouse has been constructed at the National Institutes of Health'39 and will be developed in London (Segal AW, unpublished results, June 1995). Such models may prove to be invaluable for testing correction of the genetic defect by gene transfer technologies. Also, for better understanding the clinical differences between the various subgroups of CGD and for testing new therapeutic strategies, these models may be very helpful.
Both in the United States and Europe, physicians in charge of CGD patients and investigators of NADPH oxidase have initiated a registry of CGD patients. These programs are meant to register clinical and biochemical details of the patients to ( 1) better understand incidence and ethiology of the disease; (2) provide clinicians with help from specialized centers for (prenatal) diagnosis and treatment; and (3) provide investigators with help from clinicians to obtain unique genetic material. Recently, a similar registration has been started in Japan. Hopefully, these activities will be extended to collaboration in the field of gene therapy. 
